MSC therapy for diabetic kidney disease and nephrotic syndrome
Crossref DOI link: https://doi.org/10.1038/s41581-023-00776-z
Published Online: 2023-10-02
Published Print: 2023-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lu, Bo
Lerman, Lilach O. http://orcid.org/0000-0002-3271-3887
Text and Data Mining valid from 2023-10-02
Version of Record valid from 2023-10-02
Article History
First Online: 2 October 2023
Competing interests
: L.O.L. is an advisor to CureSpec and Ribocure Pharmaceuticals. B.L. declares no competing interests.